1. Thomson AJ., Williams RJP., Reslova S.
The chemistry of complexes
related to cis-Pt(NH3)2Cl2.
An anti-tumour drug.
In: Structure Bonding 11: 1-47, 1972, Berlin.
2. Cleare MJ., Hydes PC.
Anti-tumour properties
of metal complexes.
11: 1-62, 1979. In: Metal Ions in Biological
Systems. Eds: Marcel Dekker, New York.
3. Kelman AD., Clarke MJ., Edmonds SD., Peresie
HJ.
Biological activity of
ruthenium purine complexes.
J. Clin. Hematol. Oncol. 7: 1: 274-288,
1977.
4. Stern EW.
The search for new platinum antitumor agents:
progress, problems and prospects.
In: Platinum and Other Metal Coordination
Compounds in Cancer Chemotherapy, eds: M Nicolini.
Boston 519-524, 1988.
5. Giraldi T, Sava G, Bertoli G, Mestroni G,
Zassinovich G.
Antitumor
action of two rhodium and ruthenium complexes
in comparison with cis-diamminedichloro-platinum(II).
"Cancer Res", 37: 2662-2666 (1977).
6. Sava G, Giraldi T, Mestroni G, Zassinovich
G.
Antitumor
effects of rhodium(I), iridium(I) and ruthenium(II)
complexes in comparison with cis-dichloro-diamminoplatinum(II)
in mice bearing Lewis lung carcinoma.
"Chem Biol Interactions", 45:
1-6 (1983).
7. Sava G, Zorzet S, Giraldi T, Mestroni G,
Zassinovich G.
Antineoplastic activity and toxicity of an organometallic
complex of ruthenium(II) in comparison with
cis-PDD in mice bearing solid malignant neoplasms.
"Eur J Cancer Clin Oncol", 20:
841-847 (1984).
8. Clarke MJ., Galang RD., Rodriguez VM., Kumar
R., Pell S., Bryan DM.
Chemical considerations
in the design of ruthenium anticancer agents.
In: Platinum and Other Metal Coordination
Compounds in Cancer Chemotherapy. EDS: M Nicolini,
Boston, 582-601, 1988.
9. Clarke MJ., Buchbinder M.
Binding of pentammineruthenium(III)
to double-helical and single-stranded DNA.
Inorganica Chimica Acta 27: L87-L88, 1978.
10. Mestroni G., Alessio E., Sava G., Pacor
S., Coluccia M.
The development of tumor-inhibiting
ruthenium dimethylsulfoxide complexes.
In: Metal Complexes in Cancer Chemotherapy.
Ed: BK Keppler by Verlaggesellschaft, Weiheim.
157-185, 1993a.
11. Mestroni G., Alessio E., Sava G., Pacor
S., Coluccia M., Boccarelli A.
Water-soluble ruthenium(III)-dimethylsulfoxide
complexes: chemical behaviour and pharmaceutical
properties.
Metal Based Drugs 1: 1: 41-63, 1993b.
12. Sava G.
Ruthenium compounds in
cancer therapy.
In: Metal Compounds in Cancer Therapy. Ed:
Simon Fricker, by Chapman & Hall, London.
65-91, 1994.
13. Keppler BK., Berger MR., Heim ME.
New
tumor-inhibiting metal complexes.
Cancer Treat. Rev. 17: 261-277, 1990.
14. Clarke MJ.
Ruthenium chemistry pertaining
to the design of anticancer agents.
In: Progress in Clinical Biochemistry and
Medicine, Vol: 10, Springer-Verlag Berlin, 25-39,
1989.
15. Keppler BK., Henn M., Juhl UM., Berger
MR., Niebl R., Wagner FE.
New ruthenium complexes
for the treatment of cancer.
In: Progress in Clinical Biochemistry and
Medicine, vol 10, Springer-Verlag Berlin Heidelberg
p. 41-69, 1989.
16. Sava G, Pacor S, Bregant F, Ceschia V,
Mestroni G.
Metal complexes of ruthenium: antineoplastic
properties and perspectives.
"Anti-Cancer Drugs", 1: 99-108
(1990b).
17. Luft JH.
The fine structure of
hyaline cartilage matrix following ruthenium
red fixative and staining.
J. Cell Biol. 27:61a, 1965.
18. Engfeldt B, Hjertquist SO.
Studies
on the epiphyseal growth zone.
Vierchow. Arch. [Cell Pathol.] 1: 222-229,
1968.
19. Hunziker EB., HeRuthenium Redmann W., Schenk
RK.
Improved
cartilage fixation by ruthenium hexammine trichloride
(RHT). A prerequisite for morphometry in growth
cartilage.
J. Ultrastruct. Res. 81: 1-12, 1982.
20. Hunziker EB., HeRuthenium Redmann W., Schenk
RK.
Ruthenium hexammine trichloride (RHT)-metiated
interaction between plasmalemmal components
and pericellular matrix proteoglycans is responsible
for the preservation of chondrocytic plasma
membranes in situ during cartilage fixation.
J. Histochem. Cytochem. 31: 6: 717-727,
1983.
21. Nuehring LP., Steffens WL., Rowland GN.
Comparison
of the Ruthenium hexammine trichloride method
to other methods of chemical fixation for preservation
of avian physeal cartilage.
Histochem. Journal 23: 201-214, 1991.
22. Fletcher JM., Greenfield BF., Hardy CJ.,
et al.
Ruthenium Red.
J. Chem. Soc. 2000-2006, 1961.
23. Luft JH.
Electron microscopy of
cell extraneous coats as revealed by ruthenium
red staining.
J. Cell. Biol. 23: 54a, 1964.
24. Luft JH.
Fine structure of capillary and endocapillary
layer as revealed by ruthenium red.
Fed. Proc. 25: 1773-1783, 1966.
25. Handley PS., Hargreaves J., Harty DW.
Ruthenium
red staining reveals surface fibrils and a layer
external to the cell wall in Streptococcus salivarius
HB and adhesion deficient mutants.
J. Gen. Microbiol. 134: 3165-3172, 1988.
26. Alroy J., Goyal V., Ucci AA., Klauber GT.,
Heaney JA., Choen SM.
Cell surface coat of human and rat bladder urothelium.
I. Ruthenium Red studies in non-neoplastic and
neoplastic cells.
Virchows Arch. [Cell Pathol.] 42: 251-262,
1983.
27. Ghosh L., Nassauer J., Faiferman I., Ghosh
BC.
Ultrastructural
study of membrane glycocalyx in primary and
metastatic human and rat mammary carcinoma.
J. Surg. Oncol. 17: 395-401, 1981.
28. Sugihara S., Yamamoto T., Tsuruta J., Tanaka
J., Hiroaka T., Tashiro S., Miyauchi Y., Kambara
T.
Enzyme-induced
aggregation and disaggregation of tumor cells
via the cell surface glycocalyx in association
with deoxyribonucleic acid.
Acta Pathol. Japon. 41: 5: 327-335, 1991.
29. Deinum J., Wallin M., Jensen PW.
The
binding of Ruthenium Red to tubulin.
Biochim. Biophys. Acta. 838: 197-205, 1985.
30. Moore CL.
Specific inhibition of mitochondrial Ca++
transport by ruthenium red.
Biochem. Biophys. Res.
31. Ferrari R., di Lisa F., Raddino R., Visioli
O.
The
effects of ruthenium red on mitochondrial function
during post-ischaemic reperfusion.
J. Mol. Cell. Cardiol. 14: 737-740, 1982.
32. Park Y., Bowles DK., Kehrer JP.
Protection against hypoxic
injury in isolated- perfused rat heart by ruthenium
red.
J. Pharmacol. Expl. Ther. 253: 2: 628-635,
1990.
33. Benzi RH., Lerch R.
Dissociation between contractile function and
oxidative metabolism in postischemic myocardium.
Attenuation by ruthenium red administered during
reperfusion.
Circulation Res. 71: 3: 567-576, 1992.
34. Missiaen L., De Smedt H., Droogmans G.,
Wuytack F., Raeymaekers L., Casteels R.
Ruthenium
red and compound 48/80 inhibit the smooth-muscle
plasma-membrane Ca2+ pump via interaction
with associated polyphosphoinositides.
Biochem. Biophys. Acta 1023: 449-454, 1990.
35. Wieraszko A.
Evidence that ruthenium red disturbs the synaptic
transmission in the rat hippocampal slices through
interacting with sialic acid residues.
Brain Res. 378: 120-126, 1986.
36. Groskreutz JL., Bronk SF., Gores GJ.
Ruthenium
red delays the onset of cell death during oxidative
stress of rat hepatocytes.
Gastroenterology. 102: 1030-1038, 1992.
37. Dessi F., Ben-Ari Y., Charriaut-Marlangue
C.
Ruthenium red protects against glutamate- induced
neuronal death in cerebellar culture.
Neuroscience Letters. 201: 53-56, 1995.
38. Gomis A., Gutierrez LM., Sala F., Viniegra
S., Reig JA.
Ruthenium red inhibits selectively chromaffin
cell calcium channels.
Biochem Pharmacol. 47: 2: 225-231, 1994.
39. Adams DJ., Takeda K., Umbach JA.
Inhibitors of calcium buffering depress evoked
transmitter release at the squid giant synapse.
J. Physiol. (Lond) 369: 145-159, 1985.
40. Baux G., Simonneau M., Tauc L.
Transmitter
release: ruthenium red used to demonstrate a
possible role of sialic acid containing substrates.
J. Physiol. (Lond) 291: 161-178, 1979.
41. Tapia R., Meza-Ruiz G.
Inhibition
by ruthenium red of the calcium-dependent release
of [3H]GABA in synaptosomal fractions.
Brain Res. 126: 160-166, 1977.
42. Lischka FW., Schild D.
Standing calcium gradients in olfactory receptor
neurons can be abolished by amiloride or ruthenium
red.
J. Gen. Physiol. 102: 817-831, 1993.
43. Garcha RS., Hughes AD.
Action of heparin and ruthenium red on responses
of reversibly-permeabilised rat mesenteric arteries.
Eur. J. Pharmacol. Mol. Pharmacol. Sect.
268: 319-325, 1994.
44. Vites AM., Pappano AJ.
Ruthenium
red selectively prevents ins(1,4,5)P3
but not caffeine-gated calcium release in avian
atrium.
Am. J. Physiol. 262: H268, 1992.
45. Anghileri LJ. J. Nucl. Biol. Med. 18: 155-,
1974.
46. Ando A., Ando I., Hiraki T., Hisada K.
Distribution
of 103Ru-Chloride in tumor-bearing
animals and the mechanism for accumulation in
tumor and liver.
Nucl. Med. Biol. 15: 2: 133-140, 1988.
47. Som P., Oster ZH., Matsui K., Guglielmi
G., Persson BRR., Pellettieri ML., Srivastava
SC., Richards P., Atkins HL., Brill AB.
97Ru-transferrin
uptake in tumor and abscess.
Eur. J. Nucl. Med. 8: 491-494, 1983.
48. Srivastava SC., Richards P., Meinken GE.,
Larson SM., Grunbaum Z.
Tumor uptake of radioruthenium
compounds. In: Radiopharmaceuticals Structure-Activity
Relationships.
Eds. Spencer RP. Grune & Stratton New
York, 207-223, 1981.
49. Tanabe M., Yamamoto G.
Tissue distribution of 97Ru and 103Ru
in subcutaneous tumor of rodents.
Acta Med. Okayama. 29: 431-436, 1975.
50. Waters SL.
Potential medical applications
of ruthenium isotopes.
Coordination Chemistry Reviews. 52: 171-182,
1983.
51. Srivastava SC., Mausner LF., Clarke MJ.
Radioruthenium-labeled
compounds for diagnostic tumor imaging.
In: Progress in Clinical Biochemistry and
Medicine, vol 10, Springer-Verlag, Berlin, 111-149,
1989.
52. Chan PKL., Skov KA., James BR., Farrell
NP.
A new ruthenium radiosensitizer:
RuCl2(DMSO)2(4-nitroimidazole)2.
Int. J. Radiat. Oncol. Biol. Phys. 12: 1059-1062,
1986a.
53. Farrell N.
Metal complexes as radiosensitizer.
In: Progress in Clinical Biochemistry and
Medicine, Springer-Verlag, Berlin, vol 10, 90-109,
1989.
54. Chan PKL., Skov KA., James BR., Farrell
NP.
Chromosome-damaging activity
of a ruthenium radio-sensitizer, RuCl2(DMSO)2
(4-nitroimidazole)2, in chinese hamster
ovary cells in vitro.
Chem.-Biol. Interactions, 59: 247-254, 1986b.
55. Skov KA., Farrell NP.
Radiosensitization by metal complexes of 4(5)-nitroimidazole.
Int. J. Radiat. Biol. 57: 947-958, 1990.
56. Dale LD., Tocher JH., Dyson TM., Edwards
DI., Tocher DA.
Studies on DNA damage and induction of SOS repair
by novel multifunctional bioreducible compounds.
II. A metronidazole adduct of a ruthenium-arene
compound.
Anti-Cancer Drug Design. 7: 3-14, 1992.
57. Monti-Bragadin C., Ramani L., Samer L.,
Mestroni G., Zassinovich G.
Effects
of cis-dichlorodiammineplatinum (II) and related
transition metal complexes on Escherichia coli.
Antimicrob. Agents and Chemother. 7: 6:
825-827, 1975a.
58. Monti-Bragadin C., Tamaro M., Banfi E.
Mutagenic
activity of platinum and ruthenium complexes.
Chem.-Biol. Interactions 11: 469-472, 1975b.
59. Durig JR., Danneman J., Behnke WD., Mercer
EE.
The induction of filamentous growth in Escherichia
coli by ruthenium and palladium complexes.
13: 287-294, 1976.
60. Yasbin RE., Matthews CR., Clarke MJ.
Mutagenic
and toxic effects of ruthenium.
Chem.-Biol. Interactions 31: 355-365, 1980.
61. Witkin EM.
Ultraviolet mutagenesis and inducible repair
in Escherichia coli.
Bacteriol. Rev. 40: 869-..., 1976.
62. Barton JK., Lolis E.
Chiral discrimination
in the covalent binding of bis(phenanthroline)dichlororuthenium(II)
to B-DNA.
J. Am. Chem. Soc. 107: 708-709, 1985.
63. Pyle AM., Rehmann JP., Meshoyrer R., Kumar
CV., Turro NJ., Barton JK.
Mixed-ligand complexes
of ruthenium(II): factors governing binding
to DNA.
J. Am. Chem. Soc. 111: 3051-3958, 1989.
64. Kelly JM., Feeney MM., Tossi AB., Lecomte
J-P-. Kirsch-De Mesmaeker A.
Interaction of tetra-azaphenanthrene ruthenium
complexes with DNA and oligonucleotides. A photophysical
and photochemical investigation.
Anti-cancer Drug Design 5: 69-75, 1990.
65. Loseto F., Alessio E., Mestroni G., Lacidogna
G., Nassi A., Giordano D., Coluccia M.
Interaction of RuCl2(dimethylsulphoxide)4
isomers with DNA.
Anticancer Res. 11: 1549-1554, 1991.
66. Novakova O., Kasparova J., Vrana O., van
Vliet PM., Reedijk J., Brabec V.
Correlation between cytotoxicity
and DNA binding of polypyridyl rutheniumcomplexes.
Biochemistry 34: 12369-12378, 1995.
67. Frühauf S., Zeller WJ.
New platinum, titanium,
and ruthenium complexes with different patterns
of DNA damage in rat ovarian tumour cells.
Cancer Res. 51: 2943-2948, 1991.
68. Bertolesi GE., Trigoso CI., Espada J.,
Stockert JC.
Cytochemical application of tris (2,2’-bipyridine)
ruthenium(II): fluorescence reaction with sulfated
polyanions of mast cell granules.
J. Histochem. Cytochem. 43: 5: 537-543,
1995.
69. Skotty DR., Nieman TA.
Determination of oxalate in urine and plasma
using reversed-phase ion-pair high-performance
liquid chromatography with tris(2,2’-bipyridyl)ruthenium(II)-electrogenerated
chemiluminescence detection.
J. Chromatography B 665: 27-36, 1995.
70. Sasso MG., Quina FH., Bechara EJH.
Ruthenium(II) tris(bipyridyl) ion as a luminescent
probe for oxygen uptake.
Anal. Biochem. 156: 239-243, 1986.
71. Terpetschnig E., Szmacinski H., Lakowicz
JR.
Fluorescence
polarization immunoassay of a high-molecular-weight
antigen based on a long-lifetime Ru-ligand complex
Anal. Biochem. 227: 140-147, 1995.
72. Anghileri LJ.
The in vivo inhibition of tumor growth by ruthenium
red: its relationship with the metabolism of
calcium in the tumor.
Z. Krebsforsch. 83: 213-217, 1975.
73. Tsuruo T., Iida H., Tsukagoshi S., Sakurai
Y.
Growth inhibition of Lewis lung carcinoma by
an inorganic dye, ruthenium red.
Gann, 71: 151-154, 1980.
74. Tsuruo T., Iida H., Tsukagoshi S., Sakurai
Y.
Prevention
of vinblastine-induced cytotoxicity by ruthenium
red.
Biochem. Pharmacol. 30: 213-216, 1981.
75. Conter V., Beck WT.
Impairment by ruthenium red of anticancer drug
cytotoxicity in CCRF-CEM cells.
Biochem. Pharmacol. 32: 723-726, 1983.
76. Wilberding C., Kessel D.
Effects
of ruthenium red on accumulation and cytotoxicity
of m-AMSA, vinblastine and daunorubicin in leukemia
cells.
Biochem. Pharmacol. 33: 2559-2562, 1984.
77. Clarke MJ.,
Oncological implications
of the chemistry of ruthenium. In: Metal Ions
in Biological Systems
(Siegel H. Ed.), Marcel Dekker Inc., New
York, pp 231-283, 1980.
78. Margalit R., Gray HB., Clarke MJ., Podbielski
L.
Chemical
and biological properties of pentaamineruthenium-bleomycin
complex.
Chem. Biol. Interactions, 59: 231-245, 1986.
79. Keppler BK., Rupp W.
Antitumor activity of imidazolium-bisimidazole-tetrachlororuthenate
(III). A representative of a new class of inorganic
antitumor agents.
J. Cancer Res. Clin. Oncol. 111: 166-168,
1986.
80. Keppler BK., Balzer W., Seifried V.
Synthesis and antitumor activity of triazolium-bis-(triazole)-tetrachlororuthenate
(III) and bistriazolium-triazolepenta-chlororuthenate
(III). Two representatives of a new class of
inorganic antitumor agents.
Arzneimittel-Forschung/Drug Res. 37: 770-771,
1987a.
81. Keppler BK., Wehe D., Endres H., Rupp W.
Synthesis, antitumor activity,
and X-ray structure of bis(imidazolium)(imidazole)pentachlororuthenate(III),
(ImH)2(RuImCl5).
Inorg. Chem. 26: 844-846, 1987b.
82. Keppler BK., Rupp W., Juhl UM., Endes H.,
Niebl R., Balzer W.
Synthesis, molecular structure,
and tumor-inhibiting properties of imidazolium
trans-bis(imidazole)tetrachlororuthenate(III)
and its methyl-substituted derivatives.
Inorg. Chem. 26: 4366-4370, 1987c.
83. Garzon FT., Berger MR., Keppler BK., Schmähl
D.
Comparative antitumor activity of ruthenium
derivatives with 5’-deoxy-5-fluorouridine in
chemically induced colorectal tumors in SD rats.
Cancer Chemother. Pharmacol. 19: 347-349,
1987.
84. Berger MR., Garzon FT., Keppler BK., Schmähl
D.
Efficacy
of new ruthenium complexes against chemically
induced autochthonous colorectal carcinoma in
rats.
Anticancer Res. 9: 761-766, 1989.
85. Seelig MH., Berger MR., Keppler BK.
Antineoplastic activity of three ruthenium derivatives
against chemically induced colorectal carcinoma
in rats.
J. Cancer Res. Clin. Oncol. 118: 195-200,
1992.
86. Frühauf S., Zeller WJ.
In vitro evaluation of platinum, titanium and
ruthenium metal complexes in cisplatin-sensitive
and -resistant rat ovarian tumors
Cancer Chemother. Pharmacol. 27: 301-307,
1991.
87. Sava G, Zorzet S, Perissin L, Mestroni
G, Zassinovich G, Bontempi A.
Coordination metal complexes
of Rh(I), Ir(I) and Ru(II): recent advances
on antimetastatic activity on solid mouse tumors.
"Inorganica Chimica Acta", 137:
69-71 (1987).
88. Alessio E, Attia W, Calligaris M, Cauci
S, Dolzani L, Mestroni G, MontiBragadin C, Nardin
G, Quadrifoglio F, Sava G, Tamaro M, Zorzet
S.
Metal complexes of platinum
group: the promising antitumor features of cis-dichlorotetrakis-(dimethylsulfoxide)
Ru(II) cis-RuCl2(Me2SO4) and related complexes.
In: "Platinum and other metal coordination
compounds in cancer chemotherapy" (Marino
Nicolini Ed.), pp. 617-633, Martinus Nijhoff
Publishing, Boston, (1988a).
89. Alessio E, Mestroni G, Nardin G, Attia
WM, Calligaris M, Sava G, Zorzet S.
Cis- and trans-Dihalotetrakis(dimethylsulfoxide)ruthenium(II)
Complexes (RuX2(DMSO)4; X=Cl, Br): synthesis,
structure and antitumor activity.
"Inorg Chem", 27: 4099-4106 (1988b).
90. Sava G, Pacor S, Ceschia V, Alessio E,
Mestroni G.
Trans-Ru(II)dimethylsulphoxides: antineoplastic
action on mouse tumors.
"Pharmacol Res", 21: 453-454 (1989a).
91. Sava G, Pacor S, Zorzet S, Alessio E, Mestroni
G.
Antitumour
properties of dimethylsulphoxide ruthenium(II)
complexes in the Lewis lung carcinoma system.
"Pharmacol Res", 21: 617-628 (1989b).
92. Mestroni G, Alessio E, Calligaris M, Attia
WM, Quadrifoglio F, Cauci S, Sava G, Zorzet
S, Pacor S, Monti-Bragadin C, Tamaro M, Dolzani
L.
Chemical, biological and
antitumor properties of ruthenium(II) complexes
with dimethylsulfoxide.
In: "Progress in Clinical Biochemistry
and Medicine", pp. 71-87, Springer-Verlag,
Berlin, (1989).
93. Pacor S, Luxich E, Ceschia V, Sava G, Alessio
E, Mestroni G.
Effects
of trans-RuCl2(DMSO)4 on
B16 melanoma in mice.>.
"Pharmacol Res", 21 suppl 1: 127-128
(1989).
94. Sava G, Pacor S, Bregant F, Ceschia V,
Luxich E, Alessio E, Mestroni G.
Mechanism of tumor inhibition
by the metal complex trans-RuCl2(dimethylsulphoxide)4.
"Pharmacol (Life Sci Adv)", 9:
79-84 (1990a).
95. Sava G, Pacor S, Bregant F, Ceschia V.
Metal
complexes of ruthenium: a potential class of
selective anticancer drugs.
"Anticancer Res." 11: 1103-1108
(1991).
96. Pacor S, Sava G, Bregant F, Ceschia V,
Alessio E, Mestroni G.
Antitumor action of mer-trichlorobis(dimethylsulphoxide)aminoruthenium(III)
(BBR2382) in mice bearing Lewis lung carcinoma.
In: "Metal Ions in Biology and Medicine"
(Ph Collery, LA Poirier, M Manfait, JC Etienne,
Eds), pp. 482-484, John Libbey Eurotext, Paris,
(1990).
97. Pacor S, Sava G, Ceschia V, Bregant F,
Mestroni G, Alessio E.
Antineoplastic effects
of mer-trichlorobisdimethylsulphoxideaminorutheniumIII
against murine tumors: comparison with cisplatin
and with ImH[RuIm2Cl4].
"Chem.-Biol. Interactions" 78:
223-234 (1991).
98. Sava G, Pacor S, Mestroni G, Alessio E.
Effects
of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]°
and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors.
"Anti-cancer Drugs" 3: 25-31 (1992a).
99. Pacor S, Sava G, Mestroni G, Alessio E.
Tumor inhibition and effects on host survival
time by RutheniumIII and RhodiumIII complexes
with dimethylsulphoxide ligands.
"Pharmacol. Res." 25, suppl. 1:
73-74 (1992).
100. Sava G, Pacor S, Mestroni G, Alessio E.
Na[trans-RuCl4(DMSO)Im], a metal complex of
ruthenium with antimetastatic properties.
"Clin. Exp. Metastasis", 10: 273-280
(1992b).
101. Zeller WJ., Frü hauf S., Chen G.,
Keppler BK., Frei E., Kaufmann M.
Chemoresistance
in rat ovarian tumours.
Eur. J. Cancer 27: 62-67, 1991.
102. Coluccia M, Sava G, Loseto F, Nassi A,
Boccarelli A, Giordano D, Alessio E, Mestroni
G.
Anti-leukaemic action of RuCl2(DMSO)4
isomers and prevention of brain involvement
on P388 leukaemia and on P388/DDP subline.
"Eur. J. Cancer", 29A: 1873-1879,
1993.
103. Gagliardi R, Sava G, Pacor S, Mestroni
G, Alessio E.
Antimetastatic action and toxicity on healthy
tissues of Na[trans-RuCl4(DMSO)Im] in the mouse.
"Clin. Exp. Metastasis", 12: 93-100,
1994.
104. Sava G, Pacor S, Coluccia M, Mariggiò
M, Cocchietto M, Alessio E, Mestroni G.
Response of MCa mammary
carcinoma to cisplatin and to Na[trans-RuCl4(DMSO)Im].
Selective inhibition of spontaneous lung metastases
by the ruthenium complex.
"Drug Invest.", 8: 150-161, 1994.
105. Hellmann
106. Sava G, Pacor S, Bergamo A, Cocchietto
M, Mestroni G, Alessio E.
Effects
of ruthenium complexes on experimental tumors:
irrelevance of cytotoxicity for metastasis inhibition.
"Chem.-Biol. Interct.", 95: 109-126,
1995.
107. Coluccia M, Sava G, Salerno G, Bergamo
A, Pacor S, Mestroni G, Alessio E.
Efficacy of 5-FU combined
to Na[trans-RuCl4(DMSO)Im], a novel selective
antimetastatic agent, on the survival time of
mice with P388 leukemia, P388/DDP subline and
MCa mammary carcinoma.
"Metal Based Drugs", 2: 195-199,
1995.
108. Sava G, Zorzet S, Pacor S, Mestroni G,
Zassinovich G.
Effects of two pyridinal-alkyliminerhodium(I)
complexes in mice bearing MCa mammary carcinoma
"Cancer Chemother Pharmacol",
24: 302-306 (1989).
109. Kreuser ED., Keppler BK., Berdel WE.,
Piest A., Thiel E.
Synergistic antitumor interactions between newly
synthesized ruthenium complexes and cytokines
in human colon carcinoma cell lines.
Semin. Oncol. 19 suppl 2: 73-81, 1992.
110. Sava G, Salerno G, Bergamo A, Cocchietto
M, Gaglierdi R, Alessio E, Mestroni G.
Reduction of lung metastases
by Na[trans-RuCl4(DMSO)Im] is not
coupled with the induction of chemical xenogenization.
"Metal Based Drugs", 3: 67-73,
1996a.
111. Bergamo A., Cocchietto M., Capozzi I.,
Mestroni G., Alessio E., Sava G.
Treatment
of residual metastases with Na[trans-RuCl4(DMSO)Im]
and ruthenium uptake by tumour cells.
Anti-Cancer Drugs, 7: 697-702, 1996.
112. Sava G, Capozzi I, Bergamo A, Gagliardi
R, Cocchietto M, Masiero L, Onisto M, Alessio
E, Mestroni G, Garbisa S.
Down-regulation
of tumour gelatinase/inhibitor balance and preservation
of tumour endothelium by an antimetastatic ruthenium
complex.
"Int.J. Cancer", 68: 60-66, 1996b.
